The current Huntington's disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.

Scope

Scenario based analysis and forecasts of the commercial potential of the Huntington's disease market to 2016. Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs. Strategic recommendations for maximizing the potential of drugs in this niche orphan disease market. Indication-specific sales forecasts of key pipeline drugs to 2016.

Highlights

NeuroSearch's ACR16 is set to become the market leader by 2010. Targeting a broad spectrum of symptoms, and possessing a novel mode of action, neurologists are likely to view this drug favorably when compared to current treatments. The launch of Xenazine (tetrabenazine) on the US market and further roll-out across the 5EU looks set to be a good strategic move by Prestwick Pharmaceuticals and Cambridge Laboratories. However, peak market penetration is limited by the drug's use predominantly in severe patients and its poor side-effect profile. Forecasts based on various potential patient population sizes and drug prices, identify several scenarios in which blockbuster drugs could be established in this market. A theoretical drug which could achieve this is defined.

Reasons to Purchase

Access the lucrative potential of this underdeveloped neurodegenerative disease therapeutic market. Benchmark key late-stage compounds against current leading therapies and a theoretical “ideal” treatment. Understand the opportunities in this market based on the comments of interviewed key opinion leaders and industry executives.